erlotinib hydrochloride has been researched along with diphenylamine in 3 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (diphenylamine) | Trials (diphenylamine) | Recent Studies (post-2010) (diphenylamine) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 1,006 | 44 | 441 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Al Saleh, S; Khajah, MA; Luqmani, YA; Mathew, PM | 1 |
| Chinn, DC; Gandara, DR; Holland, WS; Lara, PN; Mack, PC | 1 |
| Belli, V; Ciardiello, D; Ciardiello, F; De Falco, V; Furia, M; Giunta, EF; Kopetz, S; Martinelli, E; Martini, G; Matrone, N; Morgillo, F; Muddassir, AL; Napolitano, S; Sorokin, A; Troiani, T | 1 |
3 other study(ies) available for erlotinib hydrochloride and diphenylamine
| Article | Year |
|---|---|
Differential effect of growth factors on invasion and proliferation of endocrine resistant breast cancer cells.
Topics: Benzamides; Breast Neoplasms; Cell Movement; Cell Proliferation; Chemokine CCL5; Chromones; Collagenases; Diphenylamine; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Female; Gene Knockdown Techniques; Humans; Insulin-Like Growth Factor I; Lymphokines; MCF-7 Cells; Morpholines; Phosphorylation; Platelet-Derived Growth Factor; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Quinazolines; Receptors, Estrogen; RNA, Small Interfering; Transforming Growth Factor beta | 2012 |
Effects of AKT inhibition on HGF-mediated erlotinib resistance in non-small cell lung cancer cell lines.
Topics: Apoptosis; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Diphenylamine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Hepatocyte Growth Factor; Heterocyclic Compounds, 3-Ring; Humans; Immunoblotting; Lung Neoplasms; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; ras Proteins | 2015 |
Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression.
Topics: Antibodies, Monoclonal; B7-H1 Antigen; Cell Line, Tumor; Colorectal Neoplasms; Diphenylamine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Female; HCT116 Cells; Humans; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Sulfonamides; Treatment Outcome; Xenograft Model Antitumor Assays | 2019 |